


Claims

1. A compound of formula I



wherein X represents phenyl, naphthyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[*b*]thienyl or benzimidazolyl,

wherein each X is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a group CONR^aR^b in which R^a and R^b independently represent a C₁₋₃ alkyl group, phenyl, phenoxy, 2-pyridyl or 3-pyridyl, wherein the aromatic substituents (i.e. phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be substituted by fluoro, chloro or cyano, or

X represents a diphenylmethyl or a dipyridinylmethyl group, optionally independently substituted at the aryl group(s) by one or more cyano, halo, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂, SCH₂ (wherein the heteroatom is connected to X), CH₂CH₂ or CH=CH, wherein each carbon in Y is optionally substituted by 1 or 2 methyl groups and/or 1 or 2 fluoro,

R¹ represents H or a C₁₋₄alkyl group,

A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

Z represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each Z is optionally substituted by one or more of

the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or W is optionally substituted with a trifluoromethylsulfonyl or a 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W), as well as tautomers, optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof, with the proviso that 2-(4-chlorophenoxy)-N-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide is excluded.

2. A compound according to claim 1, in which X represents a phenyl or pyridyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or X represents a diphenylmethyl or a dipyridinylmethyl group, optionally substituted at the aryl group(s) by one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂ or SCH₂ (both in which the heteroatom is connected to X), CH₂CH₂ or CH=CH,

R¹ is hydrogen or methyl

A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W),

as well as pharmaceutically acceptable salts, thereof.

3. A compound according to claim 1 or claim 2, wherein X represents naphthyl or a heteroaryl ring selected from quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[b]thienyl, or benzimidazolyl,

5 wherein each X is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or a group CONR^aR^b in which R^a and R^b independently represent a C₁₋₃ alkyl group,

Y is OCH₂ or SCH₂ (wherein the heteroatom is connected to X), CH₂CH₂ or CH=CH,

10 R¹ is hydrogen or methyl,

A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F;

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

15 W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring
20 (fused with two adjacent aromatic carbon atoms in W),

as well as pharmaceutically acceptable salts, thereof.

4. A compound according to any of the preceding claims, wherein X represents a phenyl or pyridyl group optionally substituted by one or more halogen and is further substituted by a
25 phenyl, phenoxy, 2-pyridyl or 3-pyridyl group, wherein the substituents (*i.e.* phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be further substituted by one or more fluoro, chloro or cyano

Y is OCH₂ or SCH₂ (wherein the heteroatom is connected to X), CH₂CH₂ or CH=CH,

R¹ is hydrogen or methyl,

30 A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W), as well as pharmaceutically acceptable salts, thereof.

5. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or X represents a diphenylmethyl or a dipyridinomethyl group, optionally substituted at the aryl group(s) by one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH_2 (in which the heteroatom is connected to X),

R^1 is hydrogen,

A represents $(\text{CH}_2)_n$, wherein n is 0 or 1 and B represents $(\text{CH}_2)_m$, wherein m is 0 or 1,

R^2 represents H or, when A and B are identical and represents CH_2 , R_2 represents H or F,

Z is thienyl, furyl or pyrrolyl,

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W), as well as pharmaceutically acceptable salts thereof.

6. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or X represents a diphenylmethyl group, optionally

substituted at the phenyl group(s) by one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂ (in which the heteroatom is connected to X),

R¹ is hydrogen,

5 A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

Z is 2,5-thienyl (where position 2 is linked to group W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl,

10 isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W),

as well as pharmaceutically acceptable salts thereof.

15

7. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or X represents a diphenylmethyl group, optionally substituted at the phenyl group(s) by one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

20

Y is OCH₂ (in which the heteroatom is connected to X),

R¹ is hydrogen,

A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

25 Z is 2,5-furyl (where position 2 is linked to group W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W),

30

as well as pharmaceutically acceptable salts thereof.

8. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or X represents a diphenylmethyl group, optionally substituted (at the phenyl group(s)) by one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂ (in which the heteroatom is connected to X),

R¹ is hydrogen,

A represents (CH₂)_n, wherein n is 0 or 1 and B represents (CH₂)_m, wherein m is 0 or 1,

R² represents H or, when A and B are identical and represents CH₂, R₂ represents H or F,

Z is 1,3-1H pyrrolyl (in which the heteroatom is connected to W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl, or with one trifluoromethylsulfonyl or one 2,2-difluoro-1,3-dioxolane ring (fused with two adjacent aromatic carbon atoms in W),

as well as pharmaceutically acceptable salts thereof.

9. A compound according to any of the preceding claims, in which Z is pyrrolyl.

10. A compound according to any of the preceding claims, in which Z is 1,3-1H pyrrolyl (in which the heteroatom is connected to W).

11. A compound according to any of the preceding claims, in which W is phenyl or 2-pyridyl, optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy, trifluoromethyl or trifluoromethylsulfonyl.

12. A compound according to any of the preceding claims, in which Y is OCH₂.

13. One or more of the following compounds:

2-(3-chlorophenoxy)-N-[1-[(1-phenyl-1H-pyrrol-3-yl)methyl]piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

5 2-(3-chlorophenoxy)-*N*-(1-{[1-(2-chlorophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

10 2-(3-chlorophenoxy)-*N*-(1-{[1-(3-chlorophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-(4-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[5-(4-chlorophenyl)-2-furyl]methyl}piperidin-4-yl)acetamide

2-(3-chlorophenoxy)-*N*-[1-({1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

15 2-(3-chlorophenoxy)-*N*-{1-[3-(1*H*-pyrrol-1-yl)benzyl]piperidin-4-yl}acetamide

2-(3-chlorophenoxy)-*N*-[1-(3-pyridin-2-ylbenzyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-*N*-(1-{[5-(2,4-dichlorophenyl)-2-furyl]methyl}piperidin-4-yl)acetamide

20 2-(3-chlorophenoxy)-*N*-[1-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide

N-(1-{[1-(4-bromophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)-2-(3-chlorophenoxy)acetamide

2-(3-chlorophenoxy)-*N*-methyl-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

25 2-[(3-chlorophenyl)thio]-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(pyridin-3-yloxy)-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

30 2-[3-(trifluoromethoxy)phenoxy]-*N*-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-[3-(trifluoromethoxy)phenoxy]-N-[1-({1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

5 2-(3-fluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-cyanophenoxy)-N-[1-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)piperidin-4-yl]acetamide

10 2-(2-chlorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-N-[1-({5-[4-(trifluoromethoxy)phenyl]-2-furyl}methyl)piperidin-4-yl]acetamide

2-(3-chlorophenoxy)-N-(1-{[1-(4-cyanophenyl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

15 2-(3-cyanophenoxy)-N-(1-{[5-(2,4-dichlorophenyl)-2-furyl]methyl}piperidin-4-yl)acetamide

2-(3-cyanophenoxy)-N-[1-({1-[4-(trifluoromethoxy)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

20 2-(3-chlorophenoxy)-N-(1-{[1-(5-chloropyrimidin-2-yl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]propanamide

(2*E*)-3-(3-chlorophenyl)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acrylamide

25 2-(3,5-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(2,6-diisopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

30 2-(3-isopropylphenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(2-cyanophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(isoquinolin-5-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

5 2-(3,4-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-[(5-chloropyridin-2-yl)oxy]-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

10 2-(3-chlorophenoxy)-N-[1-({1-[6-(trifluoromethyl)pyridin-3-yl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

2-(biphenyl-3-yloxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide,

2-(4-chlorophenoxy)-2-methyl-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]propanamide,

15 2-(3-chlorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)azetidin-3-yl]acetamide

2-(diphenylmethoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide

20 2-(3-chlorophenoxy)-N-[(3*S*,4*S*)-3-fluoro-1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide,

2-(3-chlorophenoxy)-N-[(3*R*,4*R*)-3-fluoro-1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)piperidin-4-yl]acetamide


2-(3,4-difluorophenoxy)-N-[1-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)pyrrolidin-3-yl]acetamide

25 2-(3-chlorophenoxy)-N-{1-[(1-[4-[(trifluoromethyl)sulfonyl]phenyl]-1*H*-pyrrol-3-yl)methyl]piperidin-4-yl}acetamide

2-(3-chlorophenoxy)-N-(1-{1-[(2,2-difluoro-1,3-benzodioxol-5-yl)-1*H*-pyrrol-3-yl]methyl}piperidin-4-yl)acetamide

and pharmaceutically acceptable salts thereof.

14. A compound of formula Ia



(Ia)

- 5 wherein X represents a 5-10 membered aryl or a heterocyclic group selected from pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[*b*]thienyl or benzimidazolyl, wherein each X is optionally substituted by one or more of the following: cyano, halo, a
- 10 C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group CONR^aR^b in which R^a and R^b independently represent a C_{1-3} alkyl group, phenyl, phenoxy, 2-pyridyl or 3-pyridyl, wherein the aromatic substituents (i.e. phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be substituted by fluoro, chloro or cyano,
- 15 Y is OCH_2 , SCH_2 (both in which the heteroatom is connected to X), CH_2CH_2 or $\text{CH}=\text{CH}$, wherein each carbon in Y is optionally substituted by 1 or 2 methyl groups and/or 1 or 2 fluoro,
- R^1 represents H or a C_{1-4} alkyl group,
- Z represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each Z is optionally substituted by one or more of
- 20 the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro,
- W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by
- 25 one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro,

as well as tautomers, optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof,

with the proviso that 2-(4-chlorophenoxy)-*N*-{1-[4-(1,2,3-thiadiazol-4-yl)benzyl]piperidin-4-yl}acetamide is excluded.

5

15. A compound according to claim 14, in which X represents a phenyl or pyridyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂ or SCH₂ (both in which the heteroatom is connected to X) CH₂CH₂ or CH=CH,

10 R¹ is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

15 W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts, thereof.

20 16. A compound according to claim 1 or claim 2, wherein X represents naphthyl or a heteroaryl ring selected from quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofuranyl, benzo[*b*]thienyl, or benzimidazolyl,25 wherein each X is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a group CONR^aR^b in which R^a and R^b independently represent a C₁₋₃ alkyl group,

Y is OCH₂ or SCH₂ (both in which the heteroatom is connected to X) CH₂CH₂ or CH=CH, R¹ is hydrogen or methyl,

30 Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl,

pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts, thereof.

5

17. A compound according to any of the preceding claims, wherein X represents phenyl or pyridyl group optionally substituted by one or more halogen and is further substituted by a phenyl, phenoxy, 2-pyridyl or 3-pyridyl group, wherein the substituents (*i.e.* phenyl, phenoxy, 2-pyridyl or 3-pyridyl) may optionally be further substituted by one or more fluoro, chloro or cyano,

10

Y is OCH₂ or SCH₂ (both in which the heteroatom is connected to X) CH₂CH₂ or CH=CH, R¹ is hydrogen or methyl,

Z is phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl wherein each Z is optionally substituted by cyano, fluoro, chloro or trifluoromethyl,

15

W represents phenyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

20

as well as pharmaceutically acceptable salts, thereof.

18. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

25

Y is OCH₂, (in which the heteroatom is connected to X),

R¹ is hydrogen,

Z is thienyl, furyl or pyrrolyl,

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

30

as well as pharmaceutically acceptable salts thereof.

19. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

5 Y is OCH₂ (in which the heteroatom is connected to X),

R¹ is hydrogen,

Z is 2,5-thienyl (where position 2 is linked to group W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl,

10 isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts thereof.

20. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

15 Y is OCH₂ (in which the heteroatom is connected to X),

R¹ is hydrogen,

Z is 2,5-furyl (where position 2 is linked to group W),

20 W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following:

cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

as well as pharmaceutically acceptable salts thereof.

25

21. A compound according to any of the preceding claims, in which X represents a phenyl group substituted with one or more cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

Y is OCH₂ (in which the heteroatom is connected to X),

30 R¹ is hydrogen,

Z is 1,3-1*H* pyrrolyl (in which the heteroatom is connected to W),

W represents phenyl or a heterocyclic group selected from pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, isoxazolyl wherein each W is optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl,

5 as well as pharmaceutically acceptable salts thereof.

22. A compound according to any of the preceding claims, in which Z is pyrrolyl.

23. A compound according to any of the preceding claims, in which Z is 1,3-1*H* pyrrolyl
10 (in which the heteroatom is connected to W).

24. A compound according to any of the preceding claims, in which W is phenyl or 2-pyridyl, optionally substituted by one or more of the following: cyano, fluoro, chloro, trifluoromethoxy, difluoromethoxy or trifluoromethyl.

15

25. A compound according to any of the preceding claims, in which Y is OCH₂.

26. A compound of formula I as claimed in any one of claims 1 to 25 for use as a medicament.


20

27. A pharmaceutical formulation comprising a compound of formula I or formula Ia, as defined in any one of claims 1 to 25 and a pharmaceutically acceptable adjuvant, diluent or carrier.

25 28. Use of a compound of formula I or formula Ia as defined in any one of claims 1 to 25 in the preparation of a medicament for the treatment or prophylaxis of conditions associated with obesity.


29. A compound as defined in any one of claims 1 to 25 including for use in the treatment
30 of obesity.

30. A process for the preparation of compounds of formula I or formula Ia comprising reacting a compound of formula II with a compound of formula III




5 in which X, Y, Z, W, A, B, R¹ and R² are as previously defined,

31. A process for the preparation of compounds of formula I or formula Ia comprising reacting a compound of formula IV with a compound of formula V



10 in which X, Q, L, Y, Z, W, A, B, R¹ and R² are as previously defined,

32. A process for the preparation of compounds of formula I or formula Ia comprising reacting a compound of formula VI with a compound of formula VII



15 in which X, Y, S, Z, W, A, B, R¹ and R² are as previously defined,

20 33. The following compounds of formulae II, III, IV and VI, including salts thereof, which are useful as synthesis intermediates:

2-(3-chlorophenoxy)-*N*-piperidin-4-ylacetamide

2-(3-cyanophenoxy)-*N*-piperidin-4-ylacetamide

2-(3-fluorophenoxy)-*N*-piperidin-4-ylacetamide

2-(2-chlorophenoxy)-*N*-piperidin-4-ylacetamide

N-piperidin-4-yl-2-(pyridin-3-yloxy)acetamide

N-piperidin-4-yl-2-[3-(trifluoromethoxy)phenoxy]acetamide

2-phenoxy-*N*-piperidin-4-ylacetamide

5 2-(3-chlorophenoxy)-*N*-methyl-*N*-piperidin-4-ylacetamide

2-[(3-chlorophenyl)thio]-*N*-piperidin-4-ylacetamide

1-[5-(trifluoromethyl)pyridin-2-yl]-1*H*-pyrrole-3-carbaldehyde

1-(5-chloropyrimidin-2-yl)-1*H*-pyrrole-3-carbaldehyde

4-(3-formyl-1*H*-pyrrol-1-yl)benzonitrile

10 2-chloro-*N*-[1-({ 1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl } methyl)piperidin-4-yl]acetamide

1-({ 1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl } methyl)piperidin-4-amine dihydrochloride

tert-butyl[1-({ 1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl } methyl)piperidin-4-yl]carbamate

15

1-(6-trifluoromethyl-pyridin-3-yl)-1*H*-pyrrole-3-carbaldehyde

2-(3,4-difluorophenoxy)-*N*-pyrrolidin-3-ylacetamide

1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-1*H*-pyrrole-3-carbaldehyde

1-(4-Trifluoromethanesulfonyl-phenyl)-1*H*-pyrrole-3-carbaldehyde.

20

34. A method of treating obesity, psychiatric disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders and pain related disorders, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 25 to a patient in need thereof.

25

35. A method of treating obesity, type II diabetes, metabolic syndrome and prevention of type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 25 to a patient in need thereof.

30